Abstract
Hypertrophic scar and keloid are common and difficult to treat diseases in plastic surgery. Results of wound healing research over the past decades have demonstrated that transforming growth factor-b (TGF-b) plays an essential role in cutaneous scar formation. In contrast, fetal wounds, which heal without scarring, contain a lower level of TGF-b than adult wounds. How to translate the discovery of basic scientific research into the clinical treatment of wound scarring has become an important issue to both clinicians and basic researchers. The development of gene therapy techniques offers the potential to genetically modify adult wound healing to a healing process similar to fetal wounds, and thus reduces wound scarring. This article intends to review the roles of TGF-b in the formation of wound scarring, the possible strategies of antagonizing wound TGF-b, and our preliminary results of scar gene therapy, which show that wound scarring can be significantly reduced by targeting wound TGF-b.
Keywords: wound scarring, gene therapy, adenovirus, gene transfer
Current Gene Therapy
Title: TGF-b: A Fibrotic Factor in Wound Scarring and a Potential Target for Anti- Scarring Gene Therapy
Volume: 4 Issue: 1
Author(s): W. Liu, D. R. Wang and Y. L. Cao
Affiliation:
Keywords: wound scarring, gene therapy, adenovirus, gene transfer
Abstract: Hypertrophic scar and keloid are common and difficult to treat diseases in plastic surgery. Results of wound healing research over the past decades have demonstrated that transforming growth factor-b (TGF-b) plays an essential role in cutaneous scar formation. In contrast, fetal wounds, which heal without scarring, contain a lower level of TGF-b than adult wounds. How to translate the discovery of basic scientific research into the clinical treatment of wound scarring has become an important issue to both clinicians and basic researchers. The development of gene therapy techniques offers the potential to genetically modify adult wound healing to a healing process similar to fetal wounds, and thus reduces wound scarring. This article intends to review the roles of TGF-b in the formation of wound scarring, the possible strategies of antagonizing wound TGF-b, and our preliminary results of scar gene therapy, which show that wound scarring can be significantly reduced by targeting wound TGF-b.
Export Options
About this article
Cite this article as:
Liu W., Wang R. D. and Cao L. Y., TGF-b: A Fibrotic Factor in Wound Scarring and a Potential Target for Anti- Scarring Gene Therapy, Current Gene Therapy 2004; 4 (1) . https://dx.doi.org/10.2174/1566523044578004
DOI https://dx.doi.org/10.2174/1566523044578004 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Techniques and Strategies to Analyze Neural Progenitor Cell Migration
Current Pharmaceutical Biotechnology Posterior Reversible Encephalopathy Syndrome in Leukemic Children: A Sensitive Issue
Current Drug Safety Shut-Down of Translation, a Global Neuronal Stress Response:Mechanisms and Pathological Relevance
Current Pharmaceutical Design Modulation of the FGF14:FGF14 Homodimer Interaction Through Short Peptide Fragments
CNS & Neurological Disorders - Drug Targets Brain Injury Associated with Widely Abused Amphetamines: Neuroinflammation, Neurogenesis and Blood-Brain Barrier
Current Drug Abuse Reviews Carnitine Metabolism and Deficit - When Supplementation is Necessary?
Current Pharmaceutical Biotechnology Caspase-1-independent Maturation of IL-1β in Ischemic Brain Injury: is there a Role for Gelatinases?
Mini-Reviews in Medicinal Chemistry Associations of Cerebrovascular and Alzheimer’s Disease Pathology with Brain Atrophy
Current Alzheimer Research Pharmacological Neuroprotection after Perinatal Hypoxic-Ischemic Brain Injury
Current Neuropharmacology Monotherapy Versus Combination Therapy of Angiogenic and Arteriogenic Factors for the Treatment of Ischemic Disorders
Current Molecular Medicine The Effects of Obesity on the Cerebral Vasculature
Current Vascular Pharmacology Effects of Erythropoietin on Brain Function
Current Pharmaceutical Biotechnology Neurogenesis in the Adult Brain: Implications for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets Pharmacokinetics of Inter-Alpha Inhibitor Proteins and Effects on Hemostasis After Hypoxic-Ischemic Brain Injury in Neonatal Rats
Current Pharmaceutical Design Editorial (Thematic Issue: Biochemical Targets and Biomarkers for Central Nervous System Protection and Monitoring)
CNS & Neurological Disorders - Drug Targets Coagulation Disorders in Acute Lung Injury
Current Respiratory Medicine Reviews Adrenomedullin in Heart Failure: Molecular Mechanism and Therapeutic Implication
Current Hypertension Reviews Update on Sensitivity to Nonsteroidal Antiinflammatory Drugs
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Cellular Mechanisms of Brain Injury and Cell Death
Current Pharmaceutical Design Natural compound-derived epigenetic regulators targeting epigenetic readers, writers and erasers
Current Topics in Medicinal Chemistry